Working... Menu

A Clinical Trial to Evaluate Kerecis Oral™ Compared to Autogenous Free Gingival Graft (AFGG) Tissue to Augment Gingival Soft Tissue and Wound Healing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03664401
Recruitment Status : Completed
First Posted : September 10, 2018
Last Update Posted : September 13, 2018
Tufts University School of Dental Medicine
Information provided by (Responsible Party):
Kerecis Ltd.

Brief Summary:
The purpose of this study is to evaluate Omega-3 Wound™ as an alternative to autogenous free gingival grafts harvested from the palate to treat human subjects with insufficient KT (< 2 mm)

Condition or disease Intervention/treatment Phase
Mucogingival Deformity - Insufficient Keratinized Tissue Device: Kerecis Oral™ Other: Free Gingival Graft Early Phase 1

Detailed Description:

Primary objective:

The primary aim will be to see if Omega-3 Wound™ is clinically superior to tissue harvested from the palate (Autogenous Free Gingival Graft) when comparing before and after measurements of: keratinized tissue. Change in KT width from time of surgery to 6 months post-surgery (22).

Secondary objectives:

  1. Measures of periodontal health (probing depth, recession levels, bleeding on probing, plaque score, clinical attachment level, resistance to muscle pull, vestibular depth, healing time) over 3 months (at study entry, 4 weeks, 3 months and 6 months)
  2. Time of surgery
  3. Subject Discomfort Survey during healing and at 1 week and 4 weeks
  4. Subject Preference Questionnaire at month 6
  5. Safety endpoints assessed by monitoring adverse events

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, randomized controlled, split mouth (within subject) non-inferiority, single-center trial.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: A Clinical Trial to Evaluate Kerecis Oral™ Compared to Autogenous Free Gingival Graft (AFGG) Tissue to Augment Gingival Soft Tissue and Wound Healing
Actual Study Start Date : September 1, 2016
Actual Primary Completion Date : September 1, 2017
Actual Study Completion Date : December 1, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Kerecis Oral™
The Fish Skin Graft will be is cut to shape of wound bed and placed directly on the appropriate prepared recipient wound bed. The Fish skin graft has the smooth side down and the scaly side facing out. The graft will be sutured in place at either coronal end with resorbable sutures and may be secured apically if needed. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.
Device: Kerecis Oral™
Other Name: Acellular Fish Skin Graft

Active Comparator: Autogenous Free Gingival Graft

The recipient bed will be prepared at the appropriate sequential time as described. The graft will be harvested from the same side that the Free Gingival Graft is to be placed. A measurement will be made to determine the size of the donor tissue needed to be placed at the recipient site. Local anesthetic will be administered. The donor tissue will be harvested using the usual techniques. The width will be 5 mm and the length will match the predetermined measurement. The graft will be thinned as is usual practice.

The harvested palatal graft will be centered on the study tooth and placed on the appropriately prepared recipient wound bed. The graft will be sutured with resorbable sutures on the mesial and distal aspects of the tooth. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.

Other: Free Gingival Graft
A free gingival autograft from patient palate placed and secured on wound bed
Other Name: FGG

Primary Outcome Measures :
  1. Change in KT width from time of surgery to 3 months post-surgery [ Time Frame: 3 months ]
    Increase in KT Width in MM

Secondary Outcome Measures :
  1. Probing depth [ Time Frame: 3 months ]

  2. Papillary height and widht [ Time Frame: 3 months ]

  3. Horizontal recession [ Time Frame: 3 months ]

  4. Subject completed discomfort questionaire [ Time Frame: 3 months ]
    Standard questionare

  5. Bleeding on probing [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age must be at least 18 years but no more than 70 years.
  2. There must be at least two non-adjacent teeth in contralateral sides of the same jaw with an insufficient zone (≤ 2mm) of Keratinized gingiva that requires soft tissue grafting. (1-4 teeth may be treated). If adjacent teeth require grafting, only a single chosen tooth at each site will act as the test or control site, all teeth will however get the same treatment).
  3. The goal of grafting will not be root coverage.
  4. Females must have a documented negative urine pregnancy test if they are of childbearing potential.
  5. All subjects must have read, understood and signed an Informed Consent Form (approved by the institutional review board (IRB)).
  6. All subjects must be willing and able to follow study instructions and protocols.

Exclusion Criteria:

  1. Any subject that has class III/IV recession with a shallow vestibule.
  2. Any subject that has a vestibule depth of less than 7mm from the base of recession.
  3. Any subjects with systemic conditions (i.e., diabetes mellitus, HIV, cancer, bone metabolic diseases) that typically precludes periodontal surgery.
  4. Any subjects who are currently taking/received or have taken/received within two months prior to study entry, systemic corticosteroids, immunosupressive agents, radiation therapy, and/or chemotherapy which could compromise wound healing and preclude periodontal surgery. Any subjects taking intramuscular or intravenous bisphosphonates.
  5. Any subjects with any acute lesions in the areas intended for surgery/or with a history of aphthous ulcers.
  6. Any subjects who currently smoke.
  7. Any subject with molar teeth that require treatment at the time of surgery.
  8. Any subjects with teeth with Miller Grade =>2 mobility.
  9. Any patients with known hypersensitivity to bovine collagen and/or iodine (shellfish allergy).
  10. Any subjects who have received an investigational drug or biological/bioactive treatment within 30 days prior to study enrollment (medical or dental).
  11. Any subjects previously treated with any allografts at the target site(s) or immediately adjacent teeth.
  12. Any subjects who will not be able to complete the study per protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03664401

Sponsors and Collaborators
Kerecis Ltd.
Tufts University School of Dental Medicine
Layout table for investigator information
Study Chair: Nadeem Karimbux, DMD, MMSc Tufts University of Dental Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Kerecis Ltd. Identifier: NCT03664401     History of Changes
Other Study ID Numbers: 01-GING-001-Kerecis Oral
First Posted: September 10, 2018    Key Record Dates
Last Update Posted: September 13, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Congenital Abnormalities